Synthorx, Inc. focuses on prolonging and improving lives of cancer and autoimmune disorder patients. Its product pipeline is comprised of THOR-707, IL-2 Synthorin, IL-10 Synthorin, and IL-15 Synthorin. The company was founded by Floyd E. Romesberg and Court R. Turner in 2014 and is headquartered in La Jolla, CA.
Company profile
Website
CEO
Laura K. Shawver
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Medtronic • Varian Medical Systems • Conmed • Integer • Masimo • Natus Medical • LivaNova • BioPlus Acquisition • QT Imaging • Outset Medical ...
Former names
Thoratec Cardiosystems Inc, Thoratec Laboratories Corp
SEC CIK
Corporate docs
IRS number
942340464
Latest filings (excl ownership)
15-12G
Securities registration termination
20 Oct 15
EFFECT
Notice of effectiveness
19 Oct 15
EFFECT
Notice of effectiveness
19 Oct 15
EFFECT
Notice of effectiveness
19 Oct 15
EFFECT
Notice of effectiveness
19 Oct 15
25-NSE
Exchange delisting
8 Oct 15
8-K
Termination of a Material Definitive Agreement
8 Oct 15
8-K
Thoratec Shareholders Approve ST. Jude Medical’s Acquisition of Thoratec
8 Oct 15
POS AM
Prospectus update (post-effective amendment)
8 Oct 15
POS AM
Prospectus update (post-effective amendment)
8 Oct 15
Latest ownership filings
Institutional ownership, Q3 2019
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|